Abstract
Overcoming hypoxic radioresistance with chemical sensitizers has potential to improve therapeutic outcome of head and neck cancer. Squamous-cell carcinoma cell line from a patient with lingual cancer (UT-SCC-5) was exposed to moderate (1.5% pO2) and severe (0% pO2) hypoxia, known to increase in vitro uptake of 2[3H]fluorodeoxyglucosc (FDG) by neoplastic cells. [3H]FDG uptake in well oxygenated (20% pO2) UT-SCC–52 -cells incubated with 5 mM of misonidazole (MISO) or nimorazole (NIMO) increased by 101 ± 41% and 84 ± 23%, respectively. Incubation of UT-SCC-5 in 1.5% pO2 resulted in a decrease of [3H]FDG uptake by 6 ± 4% in the presence of 5 mM of MISO while it increased by 43 ± 14% with 5 mM of NIMO In 0% pO2 both drugs showed a decrease of 58 ± 6% (MISO) and 6 ± 18% (NIMO), respectively. These in vitro studies indicate differential modification of glucose metabolism by two well known radiosensitizers in air and hypoxia. Based on these observations, we suggest that imaging of head and neck cancer with 2[18F]FDG and positron emission tomography (PET) may assist in evaluation of in vivo effects of hypoxic cell sensitizers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
